Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
March 03, 2023 16:01 ET
|
Impel Pharmaceuticals
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
February 22, 2023 16:30 ET
|
Impel Pharmaceuticals
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 PercentCompany will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial...
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET
|
Impel Pharmaceuticals
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year...
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
November 08, 2022 16:21 ET
|
Impel Pharmaceuticals
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022 16:01 ET
|
Impel Pharmaceuticals
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September
September 06, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 08:05 ET
|
Impel Pharmaceuticals
Trudhesa® TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market...
Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
August 08, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)
July 19, 2022 08:00 ET
|
Impel Pharmaceuticals
CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD SEATTLE, July 19, 2022 (GLOBE NEWSWIRE) --...